For the larger subset of patients with liver PDAC metastases, our observation that there are increased LAG3+ T cells and an emphasis of LAG3-FGL1 network in liver metastasis provide an initial rationale for studying LAG3 inhibitors in combination with anti-PD1 therapy for patients with liver metastases. Here, FGL1 is linked to medical procedure.